Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Sum­mit Ther­a­peu­tics and its Chi­nese part­ner Ake­so have a few com­peti­tors now.

Mer­ck, the mak­er of the drug they’re try­ing to beat, is en­ter­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.